Drug Evaluation: Oncologic, Endocrine & Metabolic: Docetaxel (Taxotere®): current status and clinical prospects

References

• MANGATAL L, ADELINE MT, GUENARD D, GUER1111-VOEGELEIN F, POTTER P: Application of the vicinal oxyamination reaction with asymmetric induction to the hemisynthesis of taxol and analogues. Tetrahedron (1989) 45(13):4177–4190.
   Web of Science ®Google Scholar
• WALL ME, WANI C: Recent progress in plant anti-tumoragents. Presented at the 153rd National Meeting of the American Society. Miami Beach, FL (1967)Abstract M–006.
   Google Scholar
• WANT MC, TAYLOR HL, WALL ME, COGGON P, MCPHAILAT: Plant antitumor agents. VL The isolation and struc-ture of taxol, a novel antileukemic and antitumor agent from Taxus Brevifolia. J. Am. Chem. Soc. (1971) 93(9):2325–2327.
   Google Scholar
• DOUROS J, SUFNESS M: New natural products underdevelopment at the National Cancer Institute. Recent Results Cancer Res. (1981) 76:153–175.
   PubMedGoogle Scholar
• FUCHS DA, JOHNSON RK: Cytologic evidence that taxol,an antineoplastic agent from Taxus Brevifolia, acts as a mitotic spindle poison. Cancer Treat. Rep. (1978) 62(8):1219–1222.
   PubMedGoogle Scholar
• SCHIFF PB, FANT J, HORWITZ SB: Promotion of micro-tubule assembly in vitro by taxol. Nature (1979) 277(22):665–667.
   PubMedGoogle Scholar
• DENTS JN, GREENE AE, GUENARD D, GUERITTE-VOEGELEIN F, MANGATAL L, POTTER P: A highly efficient, practical approach to natural taxoL J. Am. Chem. Soc. (1988) 110(17):5917–5919.
   Web of Science ®Google Scholar
• KINGSTON DGI, MAGRI NEJITRANGSRI C: Synthesis andstructure-activity relationships of taxol derivatives as anticancer agents. New Trends in Natural Products Chem-istry (1986) 26:219–234.
   Google Scholar
• GUERITTE-VOEGELEIN F, GUENARD D, LAVELLE F, LE GOFF MT, MANGATAL L, POTTER P: Relationship between the structure of taxol analogues and their antimitotic activity. j Med. Chem. (1991) 34(3):992–998.
   PubMed Web of Science ®Google Scholar
• RINGEL I, HORWITZ SB: Studies with RP 56976 (Taxotere): a semisynthetic analogue of taxoL J. Natl.Cancer Inst. (1991) 83(4):288–291. First evidence of docetaxel mechanism.
   Google Scholar
• DIAZ JF, ANDREU JM: Assembly of purified GDP-tubulininto microtubules induced by Taxol and Taxotere: re-versibility, ligand stoichiometry, and competition. Bio-chemistry (1993) 32(11):2747–2755.
   Google Scholar
• KUMAR N: Taxol induced polymerization of purified tubulin. J. Biol. Chem. (1981) 256(20):10435–10441.
   PubMed Web of Science ®Google Scholar
• LONG BH, FAIRCHILD C, CLASS K: Taxol and Taxotere inhibit the progression of mitotic cells to G1 phase of the cell cycle. Proc. Am. Assoc. Cancer Res. (1993) 34:380, Abstract 2266.
   Google Scholar
• DERRY WB, WILSON L, JORDAN MA: Substoichiometricbinding of taxol suppresses microtubttle dynamics. Biochemistry (1995) 34(7):2203–2211.
   PubMed Web of Science ®Google Scholar
• NOGALES E, WOLF SG, KHAN IA, LUDUENA RF, DOWNING KH: Structure of tubulin at 6.5 A and location of taxol-binding site. Nature (1995) 375(6529):424–427.
   Google Scholar
• MAURER HR, ECKERT K, BISSERY MC: Taxotere® inhibits the proliferation and induces the differentiation of HL-60 and 1(562 human myeloid cell leukemia cells in vitro. Int. J. Oncol. (1993) 3(2):161–165.
   PubMed Web of Science ®Google Scholar
• First evidence of the differentiating effect of docetaxel in human leukaemia cells.
   Google Scholar
• HIRABAYASHI N, AOGI K, NISHIYAMA M, SHAK11 A, KIMT, SAEKI S, TOGE T: A study of the mechanism(s) of the action of a new class of anticancer agent, Taxotere. j Jpn. Soc. Cancer Ther. (Nippon Gan Chiryo Gakkai Shi) (1994) 29(430):338, Abstract 784.
   Google Scholar
• BHALLA K, IBRADO AM, TOURKINA E, TANG C, MAHONEYME, HUANG Y: Taxol induces internucieosomal DNA fragmentation associated with programmed cell death in human myeloid leukemia cells. Leukemia (1993) 7(4):563–568.
   PubMed Web of Science ®Google Scholar
• RIOU JF, NAUDIN A, LAVELLE F: Effects of Taxotere on murine and human tumor cells. Biochem. Biophys, Res. Comm. (1992) 187(1):164–170.
   PubMed Web of Science ®Google Scholar
• First in vitro evaluation of docetaxel cytotoxicity.
   Google Scholar
• HILL BT, WHELAN RD, SHELLARD SA, MCCLEAN S, HOSK-ING Lit: Differential cytotoxic effects of docetaxel in a range of mammalian tumour cell lines and certain drug resistant cell lines. Invest. New Drugs (1994) 12(3):169–182.
   PubMed Web of Science ®Google Scholar
• BRAAKHUIS BJM, HILL BT, DIETEL M, KELLAND LR, AAPROMS, ZOLI W, LELIEVELD P: In vitro antiproliferative activity of docetaxel (Taxotere), paclitaxel (Taxol) and cisplatin against human tumour and normal bone mar-row cells. Anticancer Res. (1994) 14(1A):205–208.
   Google Scholar
• AAPRO M, BRAA1CHUIS BJM, DIETEL M, HANAUSKE A, HILLB, KELLAND L, LELLEVELD P, SILVESTRINI R: Superior activity of Taxotere over Taxol in vitro. Proc. Am. Assoc. Cancer Res. (1992) 33:516, Abstract 3086.
   Google Scholar
• HANAUSKE AR, DEGEN D, 1-11LSENBECK SG, BISSERY MC,VON HOFF DD: Effects of taxotere and taxol on in vitro colony formation of freshly explained human tumour cells. Anticancer Drugs (1992) 3(2) :121–124 .
   PubMedGoogle Scholar
• ALBERTS DS, GARCIA D, FANTA P, LIU R, ROE D, SALMON SE: Comparative cytotoxicities of taxol and taxotere in vitro against fresh human ovarian cancers. Proc. Am. Soc. Clin. Oncol. (1992) 11:226, Abstract 719.
   Google Scholar
• VOGEL M, HILSENBECK SG, DEPENBROCK H, DAN-HAUSER-RIEDL S, BLOCK T, NEKARDA H, FELLBAUM C, AAPRO MS, BISSERY MC, RASTEI hR J, HANAUSKE AR:Preclinical activity of taxotere (RP 56976, NSC 628503) against freshly explanted clonogenic human tumour cells: comparison with taxol and conventional antineo-plastic agents. Eur. J. Cancer (1993) 29A(14):2009–2014.
   PubMed Web of Science ®Google Scholar
• SILVESTRINI R, ZAFFARONI N, ORLANDI L, ORIANA S: In vitro cytotoxic activity of taxol and taxotere on primary cultures and established cell lines of human ovarian cancer. Stem Cells (1993) 11(6):528–535.
   PubMed Web of Science ®Google Scholar
• LAVELLE F, BISSERY MC, COMBEAU C, RIOU JF, VRIGNAUDP, ANDRE S: Preclinical evaluation of docetaxel (taxotere). Semin. Oncol. (1995) 22(2):3–16.
   Web of Science ®Google Scholar
• BISSERY MC, GUENARD D, GUERIh-VOEGELEIN F, LAV-ELLE F: Experimental antitumor activity of taxotere (RP 56976, NSC 628503), a taxol analogue. Cancer Res. (1991) 51(18):4845–4852.
   PubMed Web of Science ®Google Scholar
• Extensive preclinical pharmacology in animal models.
   Google Scholar
• NICOLE= MI, LUCCHINI V, D'INCALCI M, GIAVAZZI R: Comparison of p clitaxel and docetaxel activity on human ovarian carcinoma xenografts. Eur. J. Cancer (1994) 30A(5):691–696.
   PubMed Web of Science ®Google Scholar
• BOVEN E, VENEMA-GABERSCEK E, ERKELENS CAM, BIS-SERY MC, PINEDO HM: Antitumor activity of taxotere (RP 56976, NSC 628503), a new taxol analog, in experimen-tal ovarian cancer. Ann. Oncol. (1993) 4(4)321–324.
   Google Scholar
• NIELL HB, RANGEL C, MILLER A, COX C: The activity ofantimicrotubular agents in human bladder tumor cell lines (HBTCL). Proc. Am. Assoc. Cancer Res. (1993) 34:202, Abstract 1207,
   Google Scholar
• BRAAKHLTIS BJM, KEGEL A, WELTERS MJP: The growthInhibiting effect of docetaxel (taxotere) in head and neck squamous cell carcinoma xertowafts. Cancer Lett. (1994) 81(2):151–154.
   PubMed Web of Science ®Google Scholar
• BISSERY MC, VRIGNAUD P, BAYSSAS M, LAVELLE F: Taxotere synergistic combination with cyclophos-phamide, etoposide and 5-fluorouracil in mouse tumor models. Proc . Am. Assoc, Cancer Res . (1993) 34:299, Abstract 1782.
   Google Scholar
• BISSERY MC, VRIGNAUD P, BAYSSAS M, LAVELLE F: In vivoevaluation of taxotere (RP 56976, NSC 628503) in com-bination with cisplatinnm, doxorubicin or vincristine. Proc. Am. Assoc. Cancer Res. (1992) 33:443, Abstract 2645.
   Google Scholar
• BISSERY MC, VRIGNAUD P, BAYSSAS M, LAVELLE F: Do-cetaxel (RP 56976, taxotere) efficacy as a single agent or in combination against mammary tumors in mice. Proc. Am. Assoc. Cancer Res. (1994) 35:327, Abstract 1946.
   Google Scholar
• CHOY H, RODRIGUEZ F, KOESTER S, HILSENBECK S, VON HOFF DD: Synergistic effects of taxol/taxotere on radia-tion sensitivity of human tumor celL Int.J. Radiat. Oncol. Biol. Phys. (1992) 24\(Suppl. 1):274–275, Abstract 1059.
   Google Scholar
• CABRAL F, WIBLE L, BRENNER S, BRINKLEY BR: Taxol-re-quiring mutant of Chinese hamster ovary cells with impaired mitotic spindle activity. J. Cell Biol. (1983) 97(1):30–39.
   PubMedGoogle Scholar
• DUMONTET CM, JAFFREZOU JP, DURAN GE, JORDAN MA,WILSON L, SIKIC BI: Resistance to paclitaxel (Taxol®) in KIFIA5 variants of K562 cells is associated with the overexpression of 53-Isotype of tubulin. Blood (1994) 84(10 Suppl. 1):603, Abstract 2397.
   Google Scholar
• DUMONTET CM, DURAN GE, SIKIC BI: Mechanisms of resistance to paclitaxel (Taxol®, TAX) in human sar-coma mutants derived by single-step selection. Proc. Am. Assoc. Cancer Res. (1995) 36:320, Abstract 1907.
   Google Scholar
• GUPTA RS: Taxol resistant mutants of Chinese hamster ovary cells: genetic, biochemical and cross-resistance studies. J. Cell Physiol. (1983) 114(1):137–144.
   PubMed Web of Science ®Google Scholar
• CABRAL F, BARLOW SB: Mechanism by which mammal-ian cells acquire resistance to drugs that effect micro-tubule assembly. FASEB J. (1989) 3(5):1593–1599.
   PubMed Web of Science ®Google Scholar
• RIOU JF, PETITGENET O, AYNIE I, LAVELLE F: Estab- lishment and characterization of docetaxel (taxotere) resistant human breast carcinoma (Cak/TXT) and mur-ine leukemic (P388/TXF) cell lines. Proc. Am. Assoc. Cancer Res. (1994) 35:339, Abstract 2021.
   Google Scholar
• First evidence of docetaxel resistance mechanisms.
   Google Scholar
• WILLS P, PHUNG-BA V, WARNERY A, LECHARDEUR D, RAEISSI S, HIDALGO IJ, SCHERMAN D: Polarized transport of docetaxel and vinblastine mediated by P-glycopro-tein in human intestinal human epithelial cell mono-layer. Biochem. Pharmacol. (1994) 48(7):1528–1530.
   PubMed Web of Science ®Google Scholar
• HUNTER J, JEPSON MA, TSLTRUO T, SIMMONS NL, HIRST BH: Functional expression of P-glycoprotein in apical membranes of human intestinal Caco-2 cells. Kinetics of vinblastine secretion and interaction with modula-tors. J. Biol. Chem. (1993) 268(20):14991–14997.
   Google Scholar
• FERRY DR, RUSSEL MA, KERR DJ: 0111-Taxol binding to P-glycoprotein. Br. J. Cancer (1994) 69\(Suppl. 21):9, Ab-stract 2.8.
   Google Scholar
• COLE SP, SPARKS KE, FRASER K, LOE DW, GRANT CE,WILSON GM, DECLEY RG: Pharmacological charac-terization of multidrug resistant MRP-transfected hu-man tumor cells. Cancer Res. (1994) 54(22):5902–5910.
   PubMed Web of Science ®Google Scholar
• EXTRA JM, ROUSSEAU F, BRUNO R, CLAVEL M, LE BAIL N, MARTY M: Phase I and pharmacokinetic study oftaxotere (RP 56976; NSC 628503) given as a short intra-venous infusion. Cancer Res. (1993) 53(9:1037–1042.
   PubMedGoogle Scholar
• First Phase I study of docetaxel.
   Google Scholar
• ROWINSKY EK, WRIGHT M, MONTSARRAT B, DONE-HOWER RC: Clinical pharmacology and metabolism of Taxol (paclitaxel): update 1993. Ann. Oncol. (1994) 5\(Suppl. 6):S7–S16.
   Google Scholar
• COMMERCON A, BOURZAT JD, BEZARD D, VUILHORGNE M: Partial synthesis of major human metabolites of docetaxel Tetrahedron (1994) 50(34):10289–10298.
   Google Scholar
• ZHOU-PAN XR, MARRE F, ZHOU Xj, GAUTHIER T, PLACIDIM, RAHMANI R: Preliminary characterization of taxotere metabolism using human liver microsomal fractions. Maimonide (1992) 1(2)523, Abstract 5/2.
   Google Scholar
• CRESTEIL T, MONTSARRAT B, ROVER I, WRIGHT M: Meta-bolism of docetaxel by human cytochromes P450. In-teraction with paclitaxel and other drugs. Proc. Am. Assoc. Cancer Res. (1995) 36:395, Abstract 2356.
   Google Scholar
• BISSERY MC, BOURZAT JD, COMMERCON A, FRYDMAN A,GAILLARD C, LAVELLE F, MONEGIER B, SABLES, VUILHOR-GNE M: Isolation, identification, synthesis and biologi-cal activities of docetaxel metabolites. Abstr. Pap. Am. Chem. Soc. (1994) 207(1–2):Abstract MEDI 144.
   Google Scholar
• DE VALERIOLA D, BRASSINNE C, GAILLARD C, KETTLERJP, TOMIAK E, VAN VRECKEM A, FRUEHLING J, FRYDMAN A, KERGER J, PICCART M, CHAPELLE P, BLANC C: Study of excretion balance, metabolism and protein binding of [140-radiolabelled taxotere (RP 56976, NSC 628503) in cancer patients. Proc.Am. Assoc. CancerRes. (1993) 34:373, Abstract 2221.
   Google Scholar
• FRANCIS P, BRUNO R, SEIDMAN A, NORTON L, KEMENYN, CLARK T, KRIS M, RIGAS J, HAKES T, THALER H, VLAMIS G, SPRIGGS D: Pharmacodynamics of docetaxel (taxotere) in patients with liver metastases. Proc. Am. Assoc. Cancer Res. (1994) 13:138, Abstract 346.
   Google Scholar
• TOMIAK E, PICCART MJ, KERGER S, LIPS S, AWADA A, DEVALERIOLA D, RAVOET C, LOSSIGNOL D, SCULIER JP, AUZANNET V, LE BAIL N, BAYSSAS M, KLASTERKY J: Phase I study of docetaxel administered as a 1-hour intrave-nous infusion on a weekly basis. J. Clin. Oncol. (1994) 12(7):1458–1467.
   PubMed Web of Science ®Google Scholar
• BURRIS H, IRVIN R, KUHN J, KALTER S, SMITH L, SHAFFER D, FIELDS S, WEISS G, ECKARDT J, RODRIGUEZ G, RINALDI D, WALL J, COOK G, SMITH S, VREELAND F, BAYSSAS M, LE BAIL N, VON HOFF DD: Phase I clinical trial of taxotere administered as either a 2-hour or 6-hour Intravenous infusion. J. din. Oncol. (1993) 11(5):950–958.
   PubMed Web of Science ®Google Scholar
• BISSETT D, SETANOIANS A, CASSIDY J, GRAHAM MA,CHADWICK GA, WILSON P, AUZANNET V, LE BAIL N, KAYE SB, KERR DJ: Phase I and phartnacokinetic study of taxotere (RP 56976) administered as a 24-hour infusion. Cancer Res. (1993) 53(3):523–527.
   PubMedGoogle Scholar
• AAPRO MS, ZULIAN G, ALBERTO P, BRUNO R, OULID-AISSA D, LE BAIL N: Phase I and pharmacokinetic study of RP 56976 in a new ethanol free formulation of taxotere. Ann. Oncol. (1992) 3\(Suppl. 5):Abstract B208.
   Google Scholar
• PAZDUR R, NEWMAN RA, NEWMAN BM, FUENTES A, BENVENUTO J, BREADY B, MOORE D, JAIYESIMI I, VREELAND F, BAYSSAS M, RABER MN: Phase I trial of taxotere: five day schedule. J. Natl. Cancer Inst. (1992) 84(23):1781–1788.
   PubMed Web of Science ®Google Scholar
• RAVDIN PM, VALERO V: Review of docetaxel (taxotere), a highly active new agent for the treatment of metastaticbreast cancer. Semin. Oncol. (1995) 22(2):17–21. An overview of docetaxel in advanced breast cancer.
   Google Scholar
• HENDERSON IC: Chemotherapy for metastatic disease. In: Breast Diseases (Second Edition). Harris JR, Hellman S, Henderson IC, Kinne D (Eds.). JB Lippincott Co., Philadel-phia, PA (1991):604–665.
   Google Scholar
• REICHMANN BS, SIEDMA AD, CROWN JPA: Paclitaxel and recombinant human colony stimulating factors as in-itial chemotherapy for metastatic breast cancer. J. Clin. Oncol. (1993) 11(10):1943–1951.
   PubMed Web of Science ®Google Scholar
• SEIDMAN AD, BARRET S, HUDIS C, LEPORE J, YAO TJ,GILEWSKI T, CURCIE V, CROWN J, HAKES T, BASELGA J, SKLARIN N, MOYNAHAN ME, QUINLIVAN B, TRO-CHANOWSKI B, NORTON L: Three hour Taxol infusion as initi•l (I) and as salvage (S) chemotherapy of metas-tatic breast cancer (MBC). Proc. Am. Soc. Clin. Oncol. (1994) 13:66, Abstract 65.
   Google Scholar
• TAGUCHI T, ADACHI I, ENOMOTO K, FUKUTOMI T, KOYAMA H, MORIMOTO K, OHTA J, SONO° H, SASAKI Y, TAKASHIMA N, TAKATSUKA Y, WADA T: Docetaxel (RP 56976) in advanced or recurrent breast cancer early and late Phase II clinical studies in Japan. Proc. ASCO (1994) 13:87, Abstract 152.
   Google Scholar
• NAHOLTZ JM, SPEILAMN M, FUMOLEAU BP: Metastatic breast cancer: a muhicentric randomized trial of two doses of Taxol: Interim analysis. International Associa-tionforBreast Cancer Research, Biennial Meeting (1993):A86.
   Google Scholar
• HENDERSON IC, ALLEGRA JC, WOODCOOK T, WOLFF S, BRYAN S, CARTWRIGHT K, DUKART G, HENRY D: Ran-domized trial comparing mitoxantrone with doxoru-bicin in previously treated patients with metastatic breast can. J. Clin. Oncol. (1989) 7(5):560–571.
   PubMed Web of Science ®Google Scholar
• VALERO V. WALTERS R, THERIAULT R, ESPARZA L, HOL-MES F, FRASCHINI G, PLASSE T, BELLET R, RABER M, BUZDAR A, HORTOBAGYI GN: Phase II study of do-cetaxel (taxotere) in anthracycline-refractory metas-tatic breast cancer (ARMBC). Proc. ASCO (1994) 13:470, Abstract 1636.
   Google Scholar
• WILSON WH, BERG SI, BRYANT G, WITTES RE, BATES S,FOJO A, STEINBERG SM, GOLDSPIEL BR, HERDT J, O'SHAUGHNESSY J, BALIS FM, CHABNER BA: Paclltaxel In doxorubicin-refractory or mitoxantrone-refractory breast cancer: A Phase I/11 trial of 96-hours infusion. J. Clin. Oncol. (1994) 12(8):1621–1629.
   PubMedGoogle Scholar
• FOSELLA FV, LEE JS, MURPHY WK, LIPPMAN SM, CALAYAG M, PANG A, CHASEN M, SHIN DM, GLISSON B, BENNER S, HUBER M, PEREZ-SOLER R, HONG WK, RABER M: Phase II study of docetaxel for recurrent or metastatic non-small cell lung cancer. I Clin. Oncol. (1994) 12(6):1238–1244.
   PubMed Web of Science ®Google Scholar
• FRANCIS PA, RIGAS JR, KRIS MG, PISTERS KMW, ORAZEMJP, WOOLEY KJ, HEELAN RT: Phase II trial of docetaxel In patients with stage M and IV non-small cell lung cancer./ Clin. Oncol. (1994) 12(6):1232–1237.
   Google Scholar
• MILLER VA, RIGAS JR, FRANCIS PA, GRANT SC, PISTERSKMW, VENKATRAMAN ES, WOOLLEY K, HEELAN RT: Phase 11 trial of a 75 mg/m2 dose of docetaxel with prednisone premedication for patients with advanced non-small lung cancer. Cancer (1995) 75(4):968–972.
   PubMed Web of Science ®Google Scholar
• BURRIS HA, ECKARDT J, FIELDS 5, RODRIGUEZ G, SMITH L, THURMAN A, PEACOCK N, KUHN J, HODGES 5, BELLET R, BAYSSAS M, LE BAIL N, VON HOFF D: Phase II trials of taxotere in patients with non-small cell lung cancer. Proc. ASCO (1993) 12:335, Abstract 1116.
   Google Scholar
• CERNY T, KAPLAN S, PAVLIDIS N, SCHOFFSKI P, EPEL-BAUM R, VAN MEERBEEK J, WANDERS J, FRANKLIN HR, KAYE S: Docetaxel (taxotere) is active in non-small cell lung cancer a Phase II trial of the EORTC early clinical trials group (ECM). Br. J. Cancer (1994) 70(2)384–387.
   Google Scholar
• FOSELLA FV, LEE JS, SHIN DM, CALAYAG, HUBER M, PEREZ-SOLER R, MURPHY WK, LIPPMAN S, BENNER S, GLISSON B, CHASEN M, HONG WK, RABER M: Phase ll study of docetaxel (taxotere) for advanced or metastatic platinum-refractory non-small cell lung cancer. J. Clin. Oncol. (1995) 13(3):645–651.
   PubMed Web of Science ®Google Scholar
• FOSELLA FV, LEE JS, BERILLE J, HONG WK: Summary of Phase II data of docetaxel (taxotere), an active agent inthe first- and second-line treatment of advanced non-small cell lung cancer. Semin. Oncol. (1995) 22(2 Suppl. 4):22–29.
   Google Scholar
• An overview of docetaxel in NSCLC.
   Google Scholar
• IHDE DC: Chemotherapy of lung cancer. NetvEngl.J. Med.(1992) 327(20):1434–1441.
   PubMed Web of Science ®Google Scholar
• MURPHY WK, FOSSELLA FV, WINN RJ, SHIN DM, HYNESHE, GROSS HM, DAVILLA E, LEIMERT J, DHINGRA H, RABER MN: Phase II study of taxol in patients with untreated advanced non-small cell lung cancer. J. Natl. Cancer Inst. (1993) 85(5):384–388.
   PubMed Web of Science ®Google Scholar
• CHANG AY, KIM K, GLICK J, ANDERSON T, KARP D,JOHNSON D: Phase II study of taxol, merbarone, and piroxantrone in stage IV non-small cell lung cancer: the Eastern Cooperative Group results. J. Natl. Cancer Inst. (1993) 85(5):388–394.
   PubMed Web of Science ®Google Scholar
• KAYE SB: Docetaxel (taxotere) in the treatment of solidtumors other than breast and lung cancer. Semin. Oncol. (1995) 22(2 Suppl. 4):30–33.
   Google Scholar
• FRANCIS P, SCHNEIDER J, HANN L, BALMACEDA C, BARAKAT R, PHILLIPS M, HAKES T: Phase EI trial of docetaxel in patients with platinum-refractory ad-vanced ovarian cancer. J. Clin. Oncol. (1994) 12(11):2301–2308.
   PubMed Web of Science ®Google Scholar
• Phase II study of docetaxel in ovarian cancer.
   Google Scholar
• KAVANAGH J, KUDELKA A, FREEDMAN R, EDWARDS C,BAYSSAS M, BELLET R, HARPER K, NEWMAN B, RABER M: Taxotere (docetaxel): activity in platinum refractory ovarian cancer and amelioration of toxicity. Proc. Am. Assoc. Clin. Oncol. (1994) 13:237, Abstract 732.
   Google Scholar
• AAPRO M, PUJADE-LAURAINE E, LHOMME C, LENTZ MA,LE BAIL N, FUMOLEAU P, CHEVALIER B: Phase II of taxotere in ovarian cancer. Proc. Am. Soc. Clin. Oncol. (1993) 12:256, Abstract 809.
   Google Scholar
• TRIMBLE EL, ADAMS JD, VENA D, HAWICINS MJ, FRIEDMAN MA, FISHERMAN JS, CHRISTIAN MC, CANETrA R, ONETTO N, HAYN R, ARBUCK SG: Paclitaxel for platinum refrac-tory ovarian cancer: results from the first 1000 patients registered to National Cancer Treatment Referral Cen-ter 9103. J. Clin. Oncol. (1993) 11(12):2405–2410.
   PubMed Web of Science ®Google Scholar
• DUCREUX M, ADENIS A, BLANC C, DJAZOULI K, ESTEVEZ G, CLOUET P, BAYSSAS M, BIZZARI JP, BONNETERRE J, ARMAND JP, DE FORNI M, ROUGLER P: Phase 11 study of docetaxel in pancreatic adenocarcinoma (PAC). Ann. Oncol. (1994) 5\(Suppl. 8):82, Abstract P406,
   Google Scholar
• VAN HOESEL Q, VERVEIJ J, CLAVEL M, CATIMEL G, KER-BRAT P, KERGER J, VAN OOSTEROM A, TURSZ T, VAN GLABBEKE, VAN POTTELSBERGHE C, MUORIDSEN H: Phase II study with docetaxel (taxotere) in advanced soft tissue sarcomas of the adult Proc. ASCO (1994) 13:480, Abstract 1675.
   Google Scholar
• CATIMEL G, VERWEIJ J, MATTIJSSEN V, HANAUSKE A, PICCART M, WANDERS J, FRANKLIN H, LE BAIL N, CLAVEL M, KAYE SB: Docetaxel (taxotere): an active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. Ann. Oncol. (1994) 5(6):533–537.
   PubMed Web of Science ®Google Scholar
• SULKES A, SMYTH J, SESSA C, DIRIX LY, VERMORKEN JB,KAYE S, WANDERS J, FRANKLIN H, LE BAIL N, VERWEIJ J: Docetaxel (taxotere) in advanced gastric cancer: results of a Phase II clinical trial. Br.J. Cancer (1994) 70(2):380–383.
   PubMedGoogle Scholar
• DE vcarr R, STOTER G, BLANC C, HUBERT S, VERVEIJ J: Phase II study of first-line docetaxel in patients with metastatic urothelial cancer. Ann. Oncol. (1994) 5\(Suppl. 8):67, Abstract P331.
   Google Scholar
• SMYTH JF, SMITH IE, SESSA C, SCHOFFSKI P, WANDERS J, FRANKLIN H, KAYE SB. Activity of docetaxel (taxotere) in small cell lung cancer. Eur, J. Cancer (1994) 30A(8):1058–1060.
   Google Scholar
• AAMDAL S, VERWEIJ J, PICCART M, BRUNTSCH U, PARI-DAENS R, SULKES A, KAYE S, WANDERS J, FRANKLIN H, BAYSSAS M, LE BAIL N: Taxotere in advanced malignant melanoma: a Phase II trial of the EORTC Early Clinical Group. Eur. J. Cancer (1993) 29A\(Suppl. 6):5180, Abstract 998.
   Google Scholar
• PAZDUR R, LASSERE Y, SOH LT, AJANI JA, BREADY B, SOOE, SUGARMAN S, PATT Y, ABBRUZZESE JL, LEVIN B: Phase II of docetaxel (taxotere) in metastatic colorectal carci-noma. Ann. Oncol. (1994) 5(5):468–470.
   PubMed Web of Science ®Google Scholar
• BRUNTSCH U, HEINRICH B, KAYE SB, DE MULDER PHM,VAN OOSTEROM A, PARLDAENS R, VERMORKEN JB, WAN-DERS J, FRANKLIN H, BAYSSAS M, VERWEIJ J: Docetaxel (taxotere) in advanced renal cell cancer. A Phase II trial of the EORTC Early Clinical Trials Group. Eur.J. Cancer (1994) 30A(8):1064–1067.
   Google Scholar
• Docetaxel Product Monograph (2nd Edition). Adis Interna-tional Ltd. In press.
   Google Scholar
• OULLD-AISSA D, BEHAR A, SPLELMANN M, KAYITALIRE L, CHAU A, PLASSE T, LE BAIL N: Management of fluid retention syndrome in patients treated with taxotere (docetaxel): effect of premedication. Proc. Am. Soc. Clin. Oncol. (1994) 13:465, Abstract 1614.
   Google Scholar
• VERWEIJ J, CLAVEL M, CHEVALIER B: Paclitaxel (taxol) and docetaxel (taxotere): not simply two of a kind. Ann. Oncol. (1994) 5(6):495–505.
   PubMed Web of Science ®Google Scholar
• AAPRO MS: Docetaxel (taxotere): a highly active taxoidwith manageable toxicity. Semin. Oncol. (1995) 22(2 Suppl. 4):1–2.
   Google Scholar